Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase III Trial in MMR Deficient Endometrial Cancer Patients Comparing Chemotherapy Alone Versus Dostarlimab in First Line Advanced/Metastatic Setting

NCT05201547 is registered in ClinicalTrials.gov with ARCAGY/ GINECO GROUP as lead sponsor.

NCT NCT05201547
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05201547 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase III Trial in MMR Deficient Endometrial Cancer Patients Comparing Chemotherapy Alone Versus Dostarlimab in First Line Advanced/Metastatic Setting
Lead sponsor
ARCAGY/ GINECO GROUP
Phase
Phase 3
Overall status
Active, not recruiting
Start date
April 15, 2022
Completion date
October 31, 2029
Enrollment
260 (estimated)
Sites
100

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer